Written by Tiago Vasconcelos. A review of the recent paper – ‘Adjunctive Ketamine With Relapse Prevention–Based Psychological Therapy in the Treatment of Alcohol Use Disorder’ by Grabski et al., 2021   Alcohol abuse is one of the costliest conditions affecting modern health and a high proportion of people suffering from alcohol use disorder (AUD) are  …

What do Ketamine, Alcohol and Cannabis all have in common…not much, other than they are all up for discussion in this episode of the Drug Science Podcast! This week we’re talking about ketamine with Professor Celia Morgan, a Professor of Psychopharmacology at the University of Exeter and the academic lead for Exeter Translational Addiction Partnership  …

Ketamine This week’s episode features Paul Glue, professor of Psychiatry at the Dunedin School of Medicine, University of Otago, New Zealand. With a vast experience in both academia and pharmaceutical industry, Paul Glue’s research focuses on clinical and basic science to investigate the pharmacology of drug treatments in psychiatry and the disease mechanisms of neurological  …

Ketamine, 2-(2-chlorophenyl)-2-(methylamino)-cyclohexan-1-one, is a dissociative sedative with analgesic and anaesthetic properties, now being investigated as an antidepressant, alone and as part of ketamine-assisted therapy.  Discovered in 1962 by Calvin L. Stevens, and first tested on humans in 1964, ketamine was approved for medical use by the USA in 1970 and remains widely used to this  …

The tables have been turned in this one-off special of the Drug Science podcast. In this episode, Professor David Nutt is interviewed by renowned singer-songwriter – Joss Stone. Professor Nutt is the Chair of the Drug Science Scientific Committee and currently the Edmund J Safra Professor of Neuropsychopharmacology and Head of the Neuropsychopharmacology Unit at  …

On July 14th 2020, the UK’s leading independent scientific body on drugs has launched the Drug Science Medical Psychedelics Working Group. Building off the success of the Medical Cannabis Working Group, the Medical Psychedelics Working Group is a consortium of Drug Science experts, leading academics, researchers and policy specialists, supported by industry partners. The group’s aim  …

Professor David Nutt sits down with Fiona Measham, Anna Wade & Janine Milburn for an in depth look into why drug testing is so vital at festivals and beyond. Topics discussed include; Janine’s views following her daughters accidental overdose, how drug testing works at The Loop’s facilities, tackling the idea that the practice sends ‘mixed messages’,  …

A review and analysis of the ethical considerations in off-label ketamine use for severe, treatment-resistant depression. The review concludes that further restrictions around ketamine are not neccesary and provides a set of recomendations for oversight bodies that would support safe, effective, and ethical use. Read it here

Authors: Polly Taylor, David Nutt, Val Curran, Rudi Fortson, and Graeme Henderson Published: March 11, 2016 A letter to The Lancet endorsing the WHO Expert Committee on Drug Dependence's conclusion that concerns over recreational ketamine abuse in no way outweigh ketamine's role as a life-saving anasthetic and essential medicine. For open-access to the full report  …

A version of this post was published in The Guardian Ketamine is a unique anaesthetic and analgesic that has unfortunately become a popular and harmful recreational drug. Last year, in an attempt to reduce recreational use, and on the recommendation of its Advisory Council on the Misuse of Drugs (ACMD), the UK government decided to  …

Authors: Celia J.  A. Morgan and H. Valerie Curran Published: July 21, 2011 The first comprehensive review of the drug since its classification, DrugScience's ketamine review highlighted harms such as neurological and bladder damage. For open-access to the full report of this research, see below: Access full publication